DOCSLIB.ORG

Minutes of the 612Thmeeting Ofthe State

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Minutes of the 612thmeeting ofthe State Level Expert Appraisal Committee(SEAC) held on 18/03/2020 at Committee Room, Gujarat Pollution Control Board, Sector 10A,Gandhinagar. The 612thmeeting of the State Level Expert Appraisal Committee (SEAC) was held on 18th March 2020 at Committee Room, Gujarat Pollution Control Board, Sector 10A, Gandhinagar. Following members attended the meeting: 1. Dr. Dinesh Misra, Chairman, SEAC 2. Shri S. C. Srivastav, Vice Chairman, SEAC 3. Shri V. N. Patel, Member, SEAC 4. Shri. R. J. Shah, Member, SEAC 5. Shri A. K. Muley, Member, SEAC 6. Dr. V. K. Jain, Member, SEAC 7. Shri A. V. Shah, Secretary, SEAC The regular agenda of Appraisal, Screening & Scoping/ToR / EC – Reconsiderationcases were taken up. The Committee considered the applications made by project proponents, additional details submitted as required by the SEAC/SEIAA and details furnished in the Form-1, PFR, EIA-EMP reports. Proposal No. Name and Address of the Unit Remarks 1 SIA/GJ/IND2/27657/2018 M/s. Lincoln Pharmaceutical Limited Appraisal Block No. 176 (old Block No. 95/5-B), At – Khatraj, Ta. Kalol, Dist. Gandhinagar. Category of the unit: 5(f) Project status: New Project proponent (PP) has submitted online application vide no. SIA/GJ/IND2/27657/2018 on dated 05/11/2019 for obtaining Environmental Clearance. The SEAC had recommended TOR to SEIAA and SEIAA issued TOR to PP vide their letter dated 30/10/2018. Project proponent has submitted EIA Report prepared by M/s. Bhagwati Enviro Care Pvt. Ltd., Ahmedabad based on the TOR issued by SEIAA. Public Hearing of the Project was conducted by Gujarat Pollution Control Board at Project Site of M/s. Lincoln Pharmaceutical Limited, Block No. 176 (old Block No. 95/5-B), At – Khatraj, Ta. Kalol, Dist. Gandhinagar dated 13/11/2019. This is new unit proposes for manufacturing of synthetic organic chemical as tabulated below: 612th meeting of SEAC-Gujarat, dated 18.03.2020 Page 1 of 216 Final Sr. Quantity Product Name CAS NO. Application No. Kg/Month of Product Caroverine Hydrochloride Pharmaceuti (1-[2-(Diethylamino)ethyl]-3-[(4- cals Raw methoxyphenyl)methyl]-2(1H)- Material 1 quinoxalinone monohydrochloride) 55750-05-5 100 (For Capsule Manufacturin g ) The project falls under Category B of project activity 5(f) as per the schedule of EIA Notification 2006. PP was called for presentation in the SEAC meeting dated 18/03/2020. Salient features of the project are as under: Sr. Particulars Details no. A A Total cost of Proposed Project 0.49 Crores (Rs. in Crores): Details of EMP Sr. System Approximate Approximate Basis for cost estimates No Capital cost Recurring per annum cost per (in Lac) year (Rs. In Lac) 1 Air pollution 0.0 0.5 The capital cost will be zero for Air Pollution control control because there will be no flue gas emission & process gas emission from the unit. The recurring cost will include control of fugitive emission. 2 Water 10.0 10.2 Capital cost would include cost of ETP, In capital pollution cost civil work, mechanical work, Electrical work and control piping work is included. Recurring cost is for operational phase regarding Evaporation cost of 612th meeting of SEAC-Gujarat, dated 18.03.2020 Page 2 of 216 Spray Drying etc. 3 Noise 0.0 0.25 The recurring cost would include cost of noise pollution monitoring. monitoring 4 Solid and 1.5 1.0 Capital cost would include cost of providing storage hazardous space for hazardous waste and membership of waste TSDF Fee. Recurring cost would include cost of land management filling and transportation. 5 Environment 1.5 1.0 The recurring cost would be incurred on hiring of monitoring consultants and payment of various statutory fees to and regulatory agencies. management 6 Green belt 2.0 1.0 Development of Greenbelt including Gardening and Plantation. 7 Occupational 1.0 1.0 Occupational health check up of Employees and health (OHC) workers Total 16.0 14.95 Details of CER as per OM dated 01/05/2018 2% of Total Project Cost 1.02 Lac for 2 Year (2.06 % of total Plot Area) M/s. Lincoln Pharmaceuticals Limited CER Budget: 1.02 Lacs (For Two Year) Propose Planning for CER Activity (2020-2021) Cost in Lacs/Yr 2020 2021 0.51 Lacs give to Gram Panchayat 0.51 Lacs give to Gram Panchayat Sanavad Village as per his Khatraj Village as per his requirement requirement (mention in letter) i.e. (mention in letter) i.e. provide RO plant provide RO plant for drinking water, for drinking water, help in Education help in Education Sector, Infrastcture Sector, Infrastcture Development. Development. Total: 0.51 Lacs Total: 0.51 Lacs B Total Plot area ( sq. meter) 1049 sq. m. 612th meeting of SEAC-Gujarat, dated 18.03.2020 Page 3 of 216 Green belt area 361.05 Sq. m. ( sq. meter) C Employment generation 08 D Water i Source of Water Supply Water tanker (GIDC Bore well, Surface water, Tanker supply etc...) Status of permission from the concern authority. Yes ii Water consumption (KLD) Category Quantity Remarks KLD (A) Domestic 1 (B) Gardening 2 (C) Industrial Process 0.12 Washing 1 Industrial Total 1.12 Total (A + B + C) 4.12 1) Total water requirement for the project: 4.12 KLD 2) Quantity to be recycled: 0.00 KLD 3) Total fresh water requirement: 4.12 KLD (Total water requirement = Fresh water + Recycled water) (4.12= 4.12 + 0.00) iii Waste water generation (KLD) Category Waste water Remarks KLD (A) Domestic 0.9 (B) Industrial 612th meeting of SEAC-Gujarat, dated 18.03.2020 Page 4 of 216 Process 0.13 Washing 1 Total Industrial 1.13 waste water Total [A + B] 2.03 iv Treatment facility within premises with capacity [In-house ETP (Primary, Secondary, Tertiary), MEE, Stripper, Spray Dryer, STP etc. ETP (Cap-5 KL having Primary Treatment Unit) Treatment scheme including segregation at source. After Treatment of Industrial effluent, It will be send to Common Spray Drying facility at Chhatral Environment management system Pvt. Ltd. – Dhanot For spray drying. Note: (In case of CETP discharge) : Management of waste water keeping in view direction under section 18 (1) (b) of the Water (Prevention and Control of Pollution) act, 1974 issued by CPCB regarding compliance of CETP. Not Applicable Brief note on adequacy of ZLD (In case of Zero Liquid Discharge): Unit will achieve zero liquid discharge by discharge proposed effluent to common spray dryer. v Mode of Disposal & Final meeting point Domestic: 0.9 KLPD discharge to soak pit via septic Tank. Industrial: Industrial effluent generation will be 1.13 KLPD. That will be primary treated in ETP (Having Primary Treatment Unit) and after treatment it will be send to Common Spray Drying facility at Chhatral Environment management system Pvt. Ltd. – Dhanot For spray drying. vi In case of Common facility (CF) like CETP, Common Spray dryer, Common MEE etc. Name of CF Common Spray dryer – CEMSPL Membership of Common facility (CF) (For waste water treatment) Common Spray dryer – CEMSPL vii Simplified water balance diagram with reuse / recycle of waste water 612th meeting of SEAC-Gujarat, dated 18.03.2020 Page 5 of 216 viii Reuse/Recycle details (KLD) Total reuse 0.00 KLD Source of Application Characteristics of Remarks waste water for area with waste water to be regarding reuse with quantity in reused (COD, BOD, feasibility quantity in KLD KLD (Where it TDS etc.) to reuse (From where it is used) i.e. is coming) 0.00 --- --- --- E Air i Flue gas emission details No. of Boilers/TFH/Furnaces/DG sets etc. with capacities viz. TPH, Kcal/hr, MT/hr, KVA etc. There will be no Flue gas emission from proposed activity ii Process gas emission details i.e. Type of pollutant gases (SO2, HCl, NH3, Cl2, NOx etc.) There will be no process gas emission from proposed activity. iii Fugitive emission details with its mitigation measures: As below: 612th meeting of SEAC-Gujarat, dated 18.03.2020 Page 6 of 216 Fugitive emission could occur from the storage yard of raw materials and finished products. Due to smaller batch size of the product, The storage quantity is low maintained at site and proper handling methods will be adopted. Emissions from transport of vehicles would occur to a certain extent. The emissions from traffic movements will be controlled by proper planning of the transport of raw materials and finished products to and fro from the factory premises. All the roads inside the plant will be concreted to reduce any dust emissions. Proper planning and maintenance will control the extent of fugitive emissions. During the production, the industry will carry out regular monitoring of fugitive emissions as per the factories Act. Measures taken for fugitive emission control: Proper storage of raw materials and products. Ensuring closed feeding and sampling. Establishing SOPs for start-up, shut down and maintenance operational procedures. Regular work place monitoring and ambient air quality monitoring as per post project monitoring plan. F Hazardous wastes (as per the Hazardous and Other Wastes (Management and Transboundary Movement) Rules 2016. i Sr. Type of Waste Category Quantity Management No. Collection, Storage, 12 1 ETP Waste 35.3 Transportation & Disposal at MT/Annum approved TSDF site. Collection, Storage, 72 Transportation & Disposed 2 Spent Oil/Used Oil 5.1 Lit./Yr. by selling to Registered refiners or reuse as lubricant. Collection, Storage, Discarded 2.4 Transportation & Disposed 3 Containers (Bag, 33.1 MT/Yr by selling to authorized Barrel, Drum) recycler. ii Membership details of TSDF, CHWIF etc. TSDF – Detox India PVT LTD (For HW management) iii Details of Non-Hazardous waste & its disposal Not Applicable 612th meeting of SEAC-Gujarat, dated 18.03.2020 Page 7 of 216 (MSW and others) G Solvent management, VOC emissions etc.
Recommended publications
  • FASTKILL FK-20 Antimicrobial

    FASTKILL FK-20 Antimicrobial

    SCC FASTKILL FK-20 Antimicrobial A fast-acting, broad-spectrum biocide for treating raw materials, processing water, and contaminated products Contents Product and Application Overview . 1 Field Test Results . 3 Laboratory Test Results . 7 Physical and Chemical Properties . 9 Decomposition Pathways . 10 Safe Use and Handling . 11 Health and Environment . 15 Regulatory Information . 18 Analytical Test Methods . 19 FASTKILL FK-20 Antimicrobial A fast-acting, broad-spectrum biocide for treating raw materials, processing FASTKILL FK-20 Antimicrobial quickly and economi- cally cleans up these potential sources of contamination water, and contaminated products without requiring you to shut down or delay production. FASTKILL FK-20 Antimicrobial is a fast-acting, broad- spectrum biocide that is ideal for reducing micro- In finished products, FASTKILL FK-20 can be used biological contamination in raw materials or products such effectively in combination with long-term preservatives as aqueous paints and coatings, polymers, slurries, to reduce the bio-burden on the long-term preservative adhesives, latex and resin emulsions, sizing, caulk, process and minimize the likelihood of organism tolerance. This water and specialty industrial products including inks, can lower the chances for field failure, product recall, polishes, waxes, detergents, and cleansers. product rework, and downtime. In some cases overall preservative costs may also be reduced. Many manufacturers who use biocides for in-can preservation of finished products use the same biocide FASTKILL FK-20 also serves as a fast-acting, low cost to treat stored raw materials, wash water, recycle water, preservative for aqueous formulations such as adhesives and contaminated finished product. Although long-term where short-term protection ranging from several days preservatives may eventually get the job done, they to several weeks is desired.
  • Oral Antifungal Agent Nailin® Capsules 100Mg Approved in Japan

    Oral Antifungal Agent Nailin® Capsules 100Mg Approved in Japan

    FOR IMMEDIATE RELEASE January 19, 2018 Sato Pharmaceutical Co., Ltd. Eisai Co., Ltd. ORAL ANTIFUNGAL AGENT NAILIN® CAPSULES 100MG APPROVED IN JAPAN Sato Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President and CEO: Seiichi Sato, “Sato Pharma”) obtained marketing and manufacturing approval for the oral antifungal agent NAILIN® Capsules 100mg containing the active ingredient fosravuconazole L-lysine ethanolate (“fosravuconazole”) for the treatment of onychomycosis in Japan on January 19, 2018. Sato Pharma and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) are jointly providing information on its proper use. Fosravuconazole, the active ingredient of NAILIN® Capsules 100mg, is a new triazole class oral antifungal component discovered by Eisai. Sato Pharma conducted a Phase III clinical study of the agent in patients with onychomycosis in Japan, and after confirming efficacy and safety of the agent in the study, Sato Pharma applied for marketing and manufacturing authorization in January 2017. Onychomycosis affects 1 in every 10 Japanese people, and there are an estimated approximately 11 million sufferers in Japan. With Sato Pharma now having obtained marketing and manufacturing approval for NAILIN® Capsules 100mg, as an oral treatment for onychomycosis, this is the first new treatment for the disease in approximately 20 years. By providing NAILIN® Capsules 100mg as a new option for the treatment of onychomycosis, Sato Pharma and Eisai will strive to fulfil the needs of onychomycosis patients and healthcare professionals.
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
  • For TRADENET VERSION 4.1 Sorted by Chemical Names (Last Updated on 21 Apr 2021)

    For TRADENET VERSION 4.1 Sorted by Chemical Names (Last Updated on 21 Apr 2021)

    For TRADENET VERSION 4.1 Sorted by Chemical Names (Last updated on 21 Apr 2021) CHEMICALS CLASSIFIED UNDER HS CODES CONTROLLED BY PCD(HS) OR JOINTLY CONTROLLED WITH OTHER CAs HS CODE PRODUCT CODE DESCRIPTION PRODUCT *CAS Number (AHTN CODE 2017) 29242990 (2R,3S)-N-TERT-BUTOXYCARBONYL-3-AMINO-1-CHLORO-2- PCDCAR115 162536-40-5 HYDROXY-4-PHENYLBUTANE 29242990 [(1S)-3-METHYL-1-[[(2R)-2- PCDCAR118 247068-82-2 METHYLOXIRANYL]CARBONYL]BUTYL]CARBAMIC ACID 1,1- DIMETHYLETHYL ESTER A 28521090 1-(4-CHLOROMERCURIOPHENYLAZO)-2-NAPHTHOL; MERCURY PCDMEO112 3076-91-3 ORANGE 29159090 1,1,3,3-TETRAMETHYLBUTYLPEROXY NEODECANOATE PCDTPN111 51240-95-0 29159090 1,1,3,3-TETRAMETHYLBUTYLPEROXY-2-ETHYLHEXANOATE PCDTPN112 22288-43-3 A 29096000 1,1-DI(TERT-AMYLPEROXY)CYCLOHEXANE PCDDIT116 15667-10-4 A 29096000 1,1-DI(TERT-BUTYLPEROXY)-3,3,5-TRIMETHYLCYCLOHEXANE PCDDIT112 6731-36-8 A 29096000 1,1-DI(TERT-BUTYLPEROXY)CYCLOHEXANE PCDDIT111 3006-86-8 29159090 1,1-DIMETHYL-3-HYDROXYBUTYLPEROXY NEOHEPTANOATE PCDDIM121 110972-57-1 A 29096000 1,1-DIMETHYLPROPYL-1-METHOXYCYCLOHEXYLPEROXIDE PCDDIP119 125768-93-6 29159090 1,1-DIMETHYLPROPYL 3,5,5-TRIMETHYLHEXANEPEROXOATE PCDDIT115 68860-54-8 29291090 1,3-BIS(ISOCYANATOMETHYL)CYCLOHEXANE PCDBIS114 38661-72-2 29291090 1,4-PHENYLENE DIISOCYANATE; P-PHENYL DIISOCYANATE PCDPHD111 104-49-4 29269000 1,6-DICYANOHEXANE; SUBERONITRILE PCDDIC119 629-40-3 A 29189900 2-(2,4,5-TRICHLOROPHENOXY)PROPIONIC ACID PCDTRA113 93-72-1 A 29189900 2-(2,4-DICHLOROPHENOXY)PROPANOIC ACID PCDDIA115 120-36-5 29339990 2-(P-CHLOROPHENYL)-3-CYANO-4-BROMO-5-
  • Federal Register/Vol. 84, No. 230/Friday, November 29, 2019

    Federal Register/Vol. 84, No. 230/Friday, November 29, 2019

    Federal Register / Vol. 84, No. 230 / Friday, November 29, 2019 / Proposed Rules 65739 are operated by a government LIBRARY OF CONGRESS 49966 (Sept. 24, 2019). The Office overseeing a population below 50,000. solicited public comments on a broad Of the impacts we estimate accruing U.S. Copyright Office range of subjects concerning the to grantees or eligible entities, all are administration of the new blanket voluntary and related mostly to an 37 CFR Part 210 compulsory license for digital uses of increase in the number of applications [Docket No. 2019–5] musical works that was created by the prepared and submitted annually for MMA, including regulations regarding competitive grant competitions. Music Modernization Act Implementing notices of license, notices of nonblanket Therefore, we do not believe that the Regulations for the Blanket License for activity, usage reports and adjustments, proposed priorities would significantly Digital Uses and Mechanical Licensing information to be included in the impact small entities beyond the Collective: Extension of Comment mechanical licensing collective’s potential for increasing the likelihood of Period database, database usability, their applying for, and receiving, interoperability, and usage restrictions, competitive grants from the Department. AGENCY: U.S. Copyright Office, Library and the handling of confidential of Congress. information. Paperwork Reduction Act ACTION: Notification of inquiry; To ensure that members of the public The proposed priorities do not extension of comment period. have sufficient time to respond, and to contain any information collection ensure that the Office has the benefit of SUMMARY: The U.S. Copyright Office is requirements. a complete record, the Office is extending the deadline for the extending the deadline for the Intergovernmental Review: This submission of written reply comments program is subject to Executive Order submission of written reply comments in response to its September 24, 2019 to no later than 5:00 p.m.
  • Rpt POL-TOXIC AIR POLLUTANTS 98 BY

    Rpt POL-TOXIC AIR POLLUTANTS 98 BY

    SWCAA TOXIC AIR POLLUTANTS '98 by CAS ASIL TAP SQER CAS No HAP POLLUTANT NAME HAP CAT 24hr ug/m3 Ann ug/m3 Class lbs/yr lbs/hr none17 BN 1750 0.20 ALUMINUM compounds none0.00023 AY None None ARSENIC compounds (E649418) ARSENIC COMPOUNDS none0.12 AY 20 None BENZENE, TOLUENE, ETHYLBENZENE, XYLENES BENZENE none0.12 AY 20 None BTEX BENZENE none0.000083 AY None None CHROMIUM (VI) compounds CHROMIUM COMPOUN none0.000083 AY None None CHROMIUM compounds (E649962) CHROMIUM COMPOUN none0.0016 AY 0.5 None COKE OVEN COMPOUNDS (E649830) - CAA 112B COKE OVEN EMISSIONS none3.3 BN 175 0.02 COPPER compounds none0.67 BN 175 0.02 COTTON DUST (raw) none17 BY 1,750 0.20 CYANIDE compounds CYANIDE COMPOUNDS none33 BN 5,250 0.60 FIBROUS GLASS DUST none33 BY 5,250 0.60 FINE MINERAL FIBERS FINE MINERAL FIBERS none8.3 BN 175 0.20 FLUORIDES, as F, containing fluoride, NOS none0.00000003 AY None None FURANS, NITRO- DIOXINS/FURANS none5900 BY 43,748 5.0 HEXANE, other isomers none3.3 BN 175 0.02 IRON SALTS, soluble as Fe none00 AN None None ISOPROPYL OILS none0.5 AY None None LEAD compounds (E650002) LEAD COMPOUNDS none0.4 BY 175 0.02 MANGANESE compounds (E650010) MANGANESE COMPOU none0.33 BY 175 0.02 MERCURY compounds (E650028) MERCURY COMPOUND none33 BY 5,250 0.60 MINERAL FIBERS ((fine), incl glass, glass wool, rock wool, slag w FINE MINERAL FIBERS none0.0021 AY 0.5 None NICKEL 59 (NY059280) NICKEL COMPOUNDS none0.0021 AY 0.5 None NICKEL compounds (E650036) NICKEL COMPOUNDS none0.00000003 AY None None NITROFURANS (nitrofurans furazolidone) DIOXINS/FURANS none0.0013
  • R&D Model & Portfolio

    R&D Model & Portfolio

    R&D MODEL & PORTFOLIO ADAPTED TREATMENTS FOR THE BENEFIT OF NEGLECTED PATIENTS The R&D strategies developed by DNDi since its inception aim to Phase II trials as a potential single- address the immediate needs of patients by improving existing dose oral treatment and is the first therapeutic options in the short term, whilst undertaking longer molecule to arise from DNDi’s lead term research to identify and develop entirely new compounds optimization programme. which will be valuable adapted tools, particularly for elimination targets set by the World Health Organization. Although not Leishmaniasis is a complex family necessarily breakthrough medicines, six new treatments have of diseases, and the identification been delivered to date as a result of the short-term strategy, of new compounds has proved which have brought significant benefits to patients. challenging. Compound libraries from a variety of sources have been screened and, despite the inevitable The year 2015 has been a turning are orally available compounds for loss of compounds to attrition, NCEs point for DNDi, as long-term systemic use. The most clinically from the nitroimidazole, oxaborole, investments have now filled the advanced of these are for sleeping and aminopyrazole chemical drug development pipeline with sickness: fexinidazole, which was families are undergoing lead thirteen new chemical entities identified from compound mining optimization to combat Leishmania (NCEs) included by the end of the and is a ten day oral treatment, infections, with the nitroimidazole year, the vast majority of which and SCYX-7158, which is entering VL-0690 selected to go forward to 14 › DNDi Annual Report 2015 R&D MODEL & PORTFOLIO pre-clinical development in 2015.
  • Stembook 2018.Pdf

    Stembook 2018.Pdf

    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum

    A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum

    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
  • Fosravuconazole L-Lysine Ethanolate | Medchemexpress

    Fosravuconazole L-Lysine Ethanolate | Medchemexpress

    Inhibitors Product Data Sheet Fosravuconazole L-lysine ethanolate • Agonists Cat. No.: HY-16779B CAS No.: 914361-45-8 Molecular Formula: C₃₁H₄₀F₂N₇O₈PS • Molecular Weight: 739.73 Screening Libraries Target: Fungal; Parasite Pathway: Anti-infection Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 50 mg/mL (67.59 mM; Need ultrasonic) H2O : < 0.1 mg/mL (ultrasonic) (insoluble) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 1.3518 mL 6.7592 mL 13.5184 mL Stock Solutions 5 mM 0.2704 mL 1.3518 mL 2.7037 mL 10 mM 0.1352 mL 0.6759 mL 1.3518 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.38 mM); Clear solution BIOLOGICAL ACTIVITY Description Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a prodrug of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used for candidiasis, onychomycosis and parasitemia research[1][2][3]. In Vitro Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida, Aspergillus , and Trichophyton species[1]. MCE has not independently confirmed the accuracy of these methods.
  • Surveillance of Antifungal Use in Japan Oral Medicine + Injection Change in Antifungal Use for All of Japan by Rout of Administration 1

    Surveillance of Antifungal Use in Japan Oral Medicine + Injection Change in Antifungal Use for All of Japan by Rout of Administration 1

    Surveillance of antifungal use in Japan Oral medicine + Injection Change in antifungal use for all of Japan by rout of administration 1 0.9 / day 0.8 0.7 0.6 0.5 0.4 Dose / inhabitants / 1,000 Dose 0.3 Daily 0.2 0.1 Defined 0 2013 2014 2015 2016 2017 2018 2019 Injection注射薬 内服薬Oral medicine(テルビナフィン・ホスラブコナゾールを除く (except for terbinafine and fosravuconazole) ) ホスラブコナゾールFosravuconazole テルビナフィンTerbinafine Oral medicine Change in antifungal use (oral medicine) for all of Japan 1 0.9 / day 0.8 0.7 0.6 0.5 0.4 Dose / inhabitants / 1,000 Dose 0.3 Daily 0.2 0.1 Defined 0 2013 2014 2015 2016 2017 2018 2019 フルシトシンFlucytosine ボリコナゾールVoriconazole イトラコナゾールItraconazole フルコナゾールFluconazole ホスラブコナゾールFosravuconazole テルビナフィンTerbinafine Injection Change in antifungal use (injection) for all of Japan 0.035 / day 0.03 0.025 0.02 0.015 Dose / inhabitants / 1,000 Dose 0.01 Daily 0.005 Defined 0 2013 2014 2015 2016 2017 2018 2019 Amphotericinアムホテリシン BB ミコナゾールMiconazole フルコナゾールFluconazole イトラコナゾールItraconazole Voriconazoleボリコナゾール Caspofunginカスポファンギン ミカファンギンMicafungin 〇The data are calculated from claims registered in the NDB. The data do not always reflect the precise antibiotic use because the data of patients who receive publicly funded health care are not always included. The numerical values are different from those of the surveillance of antibiotic sales (http://amrcrc.ncgm.go.jp/surveillance/020/20190902163931.html) due to the different data source. 〇The figures indicate drug utilization standardized by defined daily dose (DDD) per population and drug, called DID (DDDs/1,000 inhabitants/day) (Reference:https://www.whocc.no/atc_ddd_index/ ).
  • Mining Sudanese Medicinal Plants for Natural Compounds Against Malaria and Neglected Tropical Diseases

    Mining Sudanese Medicinal Plants for Natural Compounds Against Malaria and Neglected Tropical Diseases

    Mining Sudanese Medicinal Plants for Natural Compounds against Malaria and Neglected Tropical Diseases INAUGURALDISSERTATION zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Abdelhalim Babiker Mohamed Mahmoud aus dem Sudan Basel, 2020 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Pascal Mӓser Prof. Dr. Thomas J. Schmidt Basel, den 23.06.2020 Prof. Dr. Martin Spiess Dekan To my father Who taught me that perseverance and hard work always pays off. May your inspiring soul rest in peace. Table of Contents Acknowledgment ...................................................................................................................................................... I Abbreviations .......................................................................................................................................................... III Summary .................................................................................................................................................................... V 1. INTRODUCTION: Neglected Tropical Diseases, Drug Discovery, and the Sudan .................... 1 1.1 Neglected Tropical Diseases ............................................................................................................................ 3 1.1.1 NTDs and Sudan .........................................................................................................................................